Your Messages Inbox (38) 
Your Unread Messages
See All
Tracy Hampton, PhD
Dorothy J. Schirf, MD
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease 3. Rapid correction of low vitamin D status in nursing home residents 4. 2008 Exclusive Survey—Earnings: Good news for primary care income 5. Medicare pay-for-reporting effort draws fire from frustrated doctors
Your Article Summary
Variegate porphyria in a 46-year-old patient taking sibutramine for weight loss
Obesity Reviews, 11/06/09
Reiser M et al. – The acute hepatic porphyrias can cause life–threatening attacks of neurovisceral symptoms that mimic other acute medical conditions. Variegate porphyria caused by mutations in the protoporphyrinogen oxidase (PPOX) gene is a latent disorder characterized by exacerbations induced by fasting, alcohol consumption or certain drugs. The authors describe the case of a 46–year–old female patient presenting with a first episode of symptomatic porphyria after 10 d of sibutramine treatment for weight loss. Genetic analysis showed a heterozygous R168H hot spot mutation in the PPOX gene. A putative effect of sibutramine on the hepatic haem biosynthetic pathway and reduced food intake have likely caused this exacerbation of a porphyria attack. Although this may be the first case report of this kind, the risk of acute porphyria should be considered in patients using pharmacotherapy for obesity.
Today in Obesity...keeping you current
Receive free subspecialty "5-minute updates" via email
Carbohydrate-restricted diets for obesity and related diseases: An update
Current Atherosclerosis Reports, 11/17/09
Exercise and diet in weight management: updating what works
British Journal of Sports Medicine, 11/11/09
Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study
The Lancet - Early Online Publication, 10/23/09
Today in Pharmacology/kinetics...keeping you current
Receive free subspecialty "5-minute updates" via email
Bisphosphonate therapy: When not to monitor BMD
The Journal of Family Practice, 11/02/09
Effect of Rosiglitazone, Metformin, and Glyburide on Bone Biomarkers in Patients with Type 2 Diabetes
Journal of Clinical Endocrinology and Metabolism, 11/10/09
FDA Approves Revisions to Prescribing Information for Diabetes Medications
American Family Physician, 11/06/09
Sponsor
Article Search
Sponsor